Janux Therapeutics (JANX) Equity Ratio (2020 - 2025)
Historic Equity Ratio for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to 0.95.
- Janux Therapeutics' Equity Ratio rose 94.76% to 0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.95, marking a year-over-year increase of 94.76%. This contributed to the annual value of 0.96 for FY2024, which is 644.02% up from last year.
- Per Janux Therapeutics' latest filing, its Equity Ratio stood at 0.95 for Q3 2025, which was up 94.76% from 0.96 recorded in Q2 2025.
- Janux Therapeutics' Equity Ratio's 5-year high stood at 0.97 during Q2 2021, with a 5-year trough of 0.88 in Q2 2023.
- Moreover, its 5-year median value for Equity Ratio was 0.95 (2024), whereas its average is 0.93.
- Per our database at Business Quant, Janux Therapeutics' Equity Ratio skyrocketed by 20685.02% in 2021 and then tumbled by 871.28% in 2023.
- Quarter analysis of 5 years shows Janux Therapeutics' Equity Ratio stood at 0.96 in 2021, then fell by 8.64% to 0.88 in 2022, then grew by 2.73% to 0.91 in 2023, then grew by 6.44% to 0.96 in 2024, then dropped by 1.1% to 0.95 in 2025.
- Its last three reported values are 0.95 in Q3 2025, 0.96 for Q2 2025, and 0.96 during Q1 2025.